Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 506

1.

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ.

Am J Kidney Dis. 2012 Nov;60(5):747-69. doi: 10.1053/j.ajkd.2012.07.017. Epub 2012 Sep 19. Review.

PMID:
22999165
2.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

3.

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline.

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ.

Ann Intern Med. 2012 Apr 17;156(8):570-81. doi: 10.7326/0003-4819-156-8-201204170-00004. Review.

PMID:
22508734
4.

The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD.

Nelson RG, Tuttle KR.

Blood Purif. 2007;25(1):112-4. Epub 2006 Dec 14.

PMID:
17170547
5.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
6.

KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.

Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, Fried L.

Am J Kidney Dis. 2015 Mar;65(3):354-66. doi: 10.1053/j.ajkd.2014.10.005. Epub 2014 Nov 18. Review.

PMID:
25465166
7.

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C.

BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review.

8.

Timing of dialysis initiation, duration and frequency of hemodialysis sessions, and membrane flux: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Greer N, Ishani A, MacDonald R, Olson C, Rutks I, Wilt TJ.

Am J Kidney Dis. 2015 Nov;66(5):823-36. doi: 10.1053/j.ajkd.2014.11.031. Review.

PMID:
26498415
9.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

10.

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.

Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF.

Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792. Epub 2011 Mar 3. Review.

PMID:
21372254
11.

Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia.

Shogbon AO, Levy SB.

Am J Health Syst Pharm. 2010 May 15;67(10):798-805. doi: 10.2146/ajhp090211. Review.

PMID:
20479101
13.

Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.

Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ.

Diabet Med. 2011 Oct;28(10):1182-7. doi: 10.1111/j.1464-5491.2011.03341.x.

PMID:
21627686
14.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
15.

Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort.

Hellemons ME, Denig P, de Zeeuw D, Voorham J, Lambers Heerspink HJ.

Nephrol Dial Transplant. 2013 Mar;28(3):706-15. doi: 10.1093/ndt/gfs567. Epub 2012 Dec 21.

PMID:
23262433
16.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
17.

Intensive insulin therapy in hospitalized patients: a systematic review.

Kansagara D, Fu R, Freeman M, Wolf F, Helfand M.

Ann Intern Med. 2011 Feb 15;154(4):268-82. doi: 10.7326/0003-4819-154-4-201102150-00008. Review.

PMID:
21320942
18.
19.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
20.

Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure.

Schnell-Inderst P, Kossmann B, Fischereder M, Klauss V, Wasem J.

GMS Health Technol Assess. 2006 Jul 18;2:Doc14.

Supplemental Content

Support Center